INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 118 filers reported holding INFINITY PHARMACEUTICALS INC in Q3 2014. The put-call ratio across all filers is 2.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,000 | -60.0% | 6,988 | -22.7% | 0.00% | – |
| Q1 2022 | $10,000 | -50.0% | 9,038 | 0.0% | 0.00% | – |
| Q4 2021 | $20,000 | -35.5% | 9,038 | 0.0% | 0.00% | – |
| Q3 2021 | $31,000 | +14.8% | 9,038 | 0.0% | 0.00% | – |
| Q2 2021 | $27,000 | -95.1% | 9,038 | -97.4% | 0.00% | – |
| Q2 2017 | $548,000 | +1145.5% | 349,346 | +2430.0% | 0.00% | – |
| Q1 2017 | $44,000 | +76.0% | 13,808 | -25.5% | 0.00% | – |
| Q4 2016 | $25,000 | +127.3% | 18,534 | +154.6% | 0.00% | – |
| Q3 2016 | $11,000 | +10.0% | 7,279 | 0.0% | 0.00% | – |
| Q2 2016 | $10,000 | -74.4% | 7,279 | 0.0% | 0.00% | – |
| Q1 2016 | $39,000 | -30.4% | 7,279 | 0.0% | 0.00% | – |
| Q4 2015 | $56,000 | -5.1% | 7,279 | 0.0% | 0.00% | – |
| Q3 2015 | $59,000 | -22.4% | 7,279 | 0.0% | 0.00% | – |
| Q2 2015 | $76,000 | -28.3% | 7,279 | 0.0% | 0.00% | – |
| Q1 2015 | $106,000 | -14.5% | 7,279 | 0.0% | 0.00% | – |
| Q4 2014 | $124,000 | +18.1% | 7,279 | -5.0% | 0.00% | – |
| Q3 2014 | $105,000 | – | 7,659 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |